# Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

> **NCT00216021** · PHASE2 · COMPLETED · sponsor: **Hoosier Cancer Research Network** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00216021
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216021, "Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00216021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*